Compare Incyte Corporation (INCY) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while YieldMax NVDA Option Income Strategy ETF trades at $13.08. The key difference: Incyte Corporation is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| INCY | NVDY | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $129.93 | $17.96 |
52-Week Low | $81.61 | $11.58 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $13.06, up 2.59% today with a bullish technical signal. The ETF generates weekly dividend distributions through options strategies on NVIDIA stock, though recent news highlights concerns about opportunity cost versus direct NVIDIA ownership. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while moving averages remain bullish.
The outlook balances high income generation against capped upside potential. Investment opportunity lies in consistent weekly distributions, while primary risks include underperformance versus NVIDIA's explosive growth and the fund's strategy of selling call options that limit participation in NVIDIA's strongest rallies. The ETF appeals to income-focused investors willing to trade growth potential for regular cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
